Long-Term Survival Outcomes of Elderly Patients Treated With S-1 or Capecitabine Plus Oxaliplatin for Stage II or III Gastric Cancer: A Multicenter Cohort Study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Choi, Seohee | - |
dc.contributor.author | Min, Jae-Seok | - |
dc.contributor.author | Jeong, Sang-Ho | - |
dc.contributor.author | Yoo, Moon-Won | - |
dc.contributor.author | Son, Young-Gil | - |
dc.contributor.author | Oh, Sung Jin | - |
dc.contributor.author | Kim, Jong-Han | - |
dc.contributor.author | Park, Joong-Min | - |
dc.contributor.author | Hur, Hoon | - |
dc.contributor.author | Jee, Ye Seob | - |
dc.contributor.author | Hwang, Sun-Hwi | - |
dc.contributor.author | Jin, Sung-Ho | - |
dc.contributor.author | Lee, Sang Eok | - |
dc.contributor.author | Lee, Young-Joon | - |
dc.contributor.author | Seo, Kyung Won | - |
dc.contributor.author | Park, Sungsoo | - |
dc.contributor.author | Lee, Chang Min | - |
dc.contributor.author | Kim, Chang Hyun | - |
dc.contributor.author | Jeong, In Ho | - |
dc.contributor.author | Lee, Han Hong | - |
dc.contributor.author | Choi, Sung Il | - |
dc.contributor.author | Lee, Sang-Il | - |
dc.contributor.author | Kim, Chan-Young | - |
dc.contributor.author | Chae, Hyundong | - |
dc.contributor.author | Son, Myoung-Won | - |
dc.contributor.author | Pak, Kyung Ho | - |
dc.contributor.author | Kim, Sungsoo | - |
dc.contributor.author | Lee, Moon-Soo | - |
dc.contributor.author | Kim, Hyoung-Il | - |
dc.date.accessioned | 2022-05-09T08:40:10Z | - |
dc.date.available | 2022-05-09T08:40:10Z | - |
dc.date.issued | 2022-03 | - |
dc.identifier.issn | 2093-582X | - |
dc.identifier.issn | 2093-5641 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/57433 | - |
dc.description.abstract | Purpose: Tegafur/gimeracil/oteracil (S-1) and capecitabine plus oxaliplatin (CAPOX) are standard adjuvant chemotherapies (ACs) administered after gastrectomy to patients with stage II or III gastric cancer. However, the effcacy of AC in elderly patients remains unclear.The objective of this retrospective multicenter cohort study was to compare the effcacies of S-1 and CAPOX AC in patients aged ≥70 years.Materials and Methods: Nine hundred eighty-three patients who were treated with AC using S-1 (768 patients) or CAPOX (215 patients) were enrolled in this study. Each patient underwent AC after curative gastrectomy for stage II or III gastric cancer at one of 27 hospitals in the Republic of Korea between January 2012 and December 2013. Relapse-free survival (RFS) and overall survival (OS) were analyzed according to AC regimen and age group.Results: Of the 983 patients, 254 (25.8%) were elderly. This group had a similar RFS (P=0.099) but significantly poorer OS (p=0.003) compared with the non-elderly group.Subgroup analysis of the non-elderly group revealed no AC-associated differences in survival.Subgroup analysis of the elderly group revealed significantly better survival in the S-1 group than in the CAPOX group (RFS, P<0.001; OS, P<0.001). Multivariate analysis revealed that the CAPOX regimen was an independent poor prognostic factor for RFS (hazard ratio [HR], 1.891; 95% confidence interval [CI], 1.072–3.333; P=0.028) and OS (HR, 2.970; 95% CI, 1.550–5.692; P=0.001).Conclusions: This multicenter observational cohort study found significant differences in RFS and OS between S-1 and CAPOX AC among patients with gastric cancer aged ≥70 years. | - |
dc.format.extent | 11 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | 대한위암학회 | - |
dc.title | Long-Term Survival Outcomes of Elderly Patients Treated With S-1 or Capecitabine Plus Oxaliplatin for Stage II or III Gastric Cancer: A Multicenter Cohort Study | - |
dc.type | Article | - |
dc.identifier.doi | 10.5230/jgc.2022.22.e6 | - |
dc.identifier.bibliographicCitation | Journal of Gastric Cancer, v.22, no.1, pp 67 - 77 | - |
dc.identifier.kciid | ART002828765 | - |
dc.description.isOpenAccess | Y | - |
dc.identifier.wosid | 000785979200006 | - |
dc.identifier.scopusid | 2-s2.0-85130295608 | - |
dc.citation.endPage | 77 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 67 | - |
dc.citation.title | Journal of Gastric Cancer | - |
dc.citation.volume | 22 | - |
dc.type.docType | Article | - |
dc.publisher.location | 대한민국 | - |
dc.subject.keywordAuthor | Adjuvant chemotherapy | - |
dc.subject.keywordAuthor | Gastric cancer | - |
dc.subject.keywordAuthor | Elderly | - |
dc.subject.keywordAuthor | Survival | - |
dc.subject.keywordAuthor | Recurrence | - |
dc.subject.keywordPlus | ADJUVANT CHEMOTHERAPY | - |
dc.subject.keywordPlus | CURATIVE GASTRECTOMY | - |
dc.subject.keywordPlus | OPEN-LABEL | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalResearchArea | Gastroenterology & Hepatology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.relation.journalWebOfScienceCategory | Gastroenterology & Hepatology | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.